QR kód

Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study

Abstract Previously, we found that patients with estrogen receptor (ER)-positive, HER2-low breast cancer are resistant to neoadjuvant chemotherapy (NACT) and have worse outcomes than those who achieve pathological complete response (pCR) after NACT. This study aimed to investigate the prognosis and...

Celý popis

Uloženo v:
Hlavní autoři: Lingfeng Tang, Linshan Jiang, Xiujie Shu, Yudi Jin, Haochen Yu, Shengchun Liu
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Portfolio 2024-05-01
Edice:Scientific Reports
Témata:
Neoadjuvant chemotherapy
Breast cancer
Estrogen receptor
HER2-low
Prognosis
On-line přístup:https://doi.org/10.1038/s41598-024-62592-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky